These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 38298707)

  • 1. Current state of immune checkpoints therapy for glioblastoma.
    Wang H; Yang J; Li X; Zhao H
    Heliyon; 2024 Jan; 10(2):e24729. PubMed ID: 38298707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint in Glioblastoma: Promising and Challenging.
    Huang J; Liu F; Liu Z; Tang H; Wu H; Gong Q; Chen J
    Front Pharmacol; 2017; 8():242. PubMed ID: 28536525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
    Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
    J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.
    Zhang N; Wei L; Ye M; Kang C; You H
    Front Immunol; 2020; 11():592612. PubMed ID: 33329578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
    Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
    Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
    Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
    Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
    Front Immunol; 2021; 12():637146. PubMed ID: 34025646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of glioblastoma immunotherapy.
    Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
    J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Biomarkers for Immunotherapy in Glioblastoma.
    Mensali N; Inderberg EM
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in GBM.
    Lee EQ
    J Neurooncol; 2021 Oct; 155(1):1-11. PubMed ID: 34599480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential.
    Yang T; Kong Z; Ma W
    Hum Vaccin Immunother; 2021 Feb; 17(2):546-553. PubMed ID: 32643507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions.
    Fathi M; Razavi SM; Sojoodi M; Ahmadi A; Ebrahimi F; Namdar A; Hojjat-Farsangi M; Gholamin S; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2022 Nov; 26(11):949-961. PubMed ID: 36527817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint: Inspecting the barriers in glioblastoma immunotherapies.
    Preddy I; Nandoliya K; Miska J; Ahmed AU
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):473-481. PubMed ID: 35150865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma.
    Abdel-Rahman SA; Gabr M
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.